Results 41 to 50 of about 4,367 (184)

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study [PDF]

, 2023
INTRODUCTION: Atopic dermatitis (AD) is a heterogeneous disease, with involvement of the T-helper cell (Th) 2, Th22, and potentially Th17 pathways, supporting the use of interleukin (IL)-23 and IL-22 blockade in AD.
Tada, Yayoi, Liu, Jie, Messina, Izabella, Tyring, Stephen K, Beeck, Stefan, Rich, Phoebe, Huang, Xiaohong, Shumack, Stephen   +7 more
core   +1 more source

Impact of BMI and Body Weight on Clinical Outcomes in Psoriasis: A Post Hoc Analysis of the RESOLVE Observational Study

JEADV Clinical Practice, EarlyView.
This post‐hoc analysis of the Greek real‐world ReSOLVE study compared clinical and patient‐reported outcomes by body weight (< 100 kg vs. ≥ 100 kg) and BMI over 52 weeks. Patients ≥ 100 kg showed delayed PASI and sPGA responses at W24 and W52, while BMI had little impact. Quality‐of‐life improvements were substantial, though early gains were smaller in
Pantelis Panagakis, Kanella Kalapothakou, Despina Exadactylou, Ioanna Lefaki, Marina Papoutsaki, Natalia Rompoti, Dimitrios Xekardakis, Nikolaos Fekkas, Efthymios Stathatos, Athanasios Chaniotis, Electra Nicolaidou, Alexandros Stratigos, Vasiliki Chasapi   +12 more
wiley   +1 more source

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial

Rheumatology and Therapy
Introduction Patients with psoriatic arthritis (PsA) require treatment providing durable long-term efficacy in different disease domains as well as safety.
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Kyle Carter, Ralph Lippe, Huzefa Photowala, Leonidas Drogaris, Ahmed M. Soliman, Michael Chen, Byron Padilla, Frank Behrens   +12 more
doaj   +1 more source

Assessment of Major Adverse Cardiovascular Event Across Diverse Racial Groups of Psoriasis Patients on Biologic Therapy: A Retrospective Cohort Study

The Journal of Dermatology, EarlyView.
ABSTRACT Psoriasis is associated with an increased risk of major adverse cardiovascular events (MACE), and biologic therapy may reduce this risk by targeting systemic inflammation. However, limited data exist on whether long term MACE risk differs by biologic class or across racial groups. We conducted a retrospective cohort study to assess the risk of
Chunghwan Ro, Ana Ormaza Vera, Waleed Adawi, Clinton W. Enos   +3 more
wiley   +1 more source

Open-label extension of a phase 2 trial of risankizumab in patients with moderate-to-severe Crohn's disease [PDF]

, 2018
Background: Risankizumab, an anti-interleukin-23 antibody, was superior to placebo in achieving clinical and endoscopic remission at week 12 in a randomised, phase 2 induction study in patients with moderately to severely active Crohn’s disease.

core   +2 more sources

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic psoriasis treatment options have rapidly expanded in Japan, including the approval of tyrosine kinase 2 and interleukin‐36 receptor inhibitors in 2022. However, contemporary real‐world treatment patterns across plaque, erythrodermic, and generalized pustular psoriasis remain incompletely characterized.
Yayoi Tada, Yoshiko Maeda, Miyuki Hasegawa, Motonobu Sakaguchi, Takamasa Hashimoto, Teruko Narusawa, Nobuyoshi Takabayashi, Tomoko Takahashi, Taisuke Kondo, Shingo Kuroda   +9 more
wiley   +1 more source

Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials [PDF]

IMPORTANCE The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit of IL-23) for the treatment of ulcerative colitis are unknown.
Parkes, Gareth, Sanchez Gonzalez, Yuri, Boland, Brigid S, Panaccione, Remo, Bossuyt, Peter, Kalabic, Jasmina, Ferrante, Marc, D'Haens, Geert, Cheng, Ling, Levine, Phillip, Atreya, Raja, Schreiber, Stefan, Chen, Su, Armuzzi, Alessandro, Duan, W Rachel, Neimark, Ezequiel, Wu, Kaichun, Biedermann, Luc, Loftus, Edward V Jr, Pivorunas, Valerie, Biedermann, Luc; https://orcid.org/, Wallace, Kori, Melmed, Gil Y, Rahier, Jean-François, Louis, Edouard, Shu, Lei, Loftus, Edward V, Hisamatsu, Tadakazu, Siegmund, Britta, Dewit, Olivier, D'Cunha, Ronilda, Colombel, Jean-Frederic, INSPIRE and COMMAND Study Group, INSPIRE and COMMAND Study, Peyrin-Biroulet, Laurent   +34 more
core   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Effect of Anti‐IL‐23 and Anti‐IL‐17 Therapy on Darier Disease: A Case Series

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater
Maione Vincenzo, Zanghi Silvia, Catapano Cecilia, Bighetti Stefano, Cattaneo Isacco, Venturini Marina, Bettolini Luca   +6 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, EarlyView.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source